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Abstract
Background: In a previously published pilot study we explored the performance of microarrays in
predicting clinical behaviour of ovarian tumours. For this purpose we performed microarray analysis on
20 patients and estimated that we could predict advanced stage disease with 100% accuracy and the
response to platin-based chemotherapy with 76.92% accuracy using leave-one-out cross validation
techniques in combination with Least Squares Support Vector Machines (LS-SVMs).
Methods: In the current study we evaluate whether tumour characteristics in an independent set of 49
patients can be predicted using the pilot data set with principal component analysis or LS-SVMs.
Results: The results of the principal component analysis suggest that the gene expression data from stage
I, platin-sensitive advanced stage and platin-resistant advanced stage tumours in the independent data set
did not correspond to their respective classes in the pilot study. Additionally, LS-SVM models built using
the data from the pilot study – although they only misclassified one of four stage I tumours and correctly
classified all 45 advanced stage tumours – were not able to predict resistance to platin-based
chemotherapy. Furthermore, models based on the pilot data and on previously published gene sets related
to ovarian cancer outcomes, did not perform significantly better than our models.
Conclusion: We discuss possible reasons for failure of the model for predicting response to platin-based
chemotherapy and conclude that existing results based on gene expression patterns of ovarian tumours
need to be thoroughly scrutinized before these results can be accepted to reflect the true performance
of microarray technology.
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Background
Ovarian cancer ranks fifth when considering cancer mor-
tality in women [1]. Unfortunately clinical or pathologic
variables that can reliably predict recurrence in FIGO
(Fédération Internationale de Gynécologie Obstétrique)
stage I patients or resistance to platin-based chemother-
apy in advanced stage disease (FIGO stage III or IV) are
not available. The prognosis might be more optimally
predicted based on gene expression analysis, since micro-
arrays can capture tumour properties that might not be
reflected in the commonly used clinical or histopatholog-
ical variables at diagnosis.
Previously, we performed a pilot study consisting of
microarray analysis on three groups of patients: seven
stage I without recurrence, seven platin-sensitive
advanced stage and six platin-resistant advanced stage
ovarian tumours [2]. We investigated whether gene
expression analysis can be used to distinguish between
stage I and advanced stage ovarian tumours, and between
platin-sensitive and platin-resistant ovarian tumours. The
results showed that a considerable number of genes were
differentially expressed between the different tumour
classes. This was confirmed by principal component anal-
ysis (PCA) where the distinction between the three
tumour classes was visualised. A least squares support vec-
tor machine (LS-SVM) analysis showed that the estimated
classification performance was 100% for the distinction
between stage I and advanced stage disease, and 76.92%
for the distinction between platin-sensitive and platin-
resistant disease when using a leave-one-out approach.
These results indicated that gene expression analysis could
be appropriate to predict prognosis of ovarian tumours.
However, since leave-one-out cross validation can overes-
timate the performance of a model, an independent eval-
uation is needed to have an unbiased estimate of the
generalization capacity.
In the current study, we describe results of an independent
evaluation of models for predicting disease stage and
response to platin-based chemotherapy built on the data
of the pilot. Our goal was to evaluate whether an inde-
pendent study could confirm the applicability of microar-
rays for the clinical management of ovarian cancer. This
independent evaluation was carried out on a set of 49 new
tumour samples which were subjected to the same exper-
imental protocol. This data set was used as a test set to esti-
mate the performance when predicting the difference
between stage I and advanced stage disease, and between
platin-sensitive and platin-resistant disease using models
trained on the pilot data set. After presenting the results,
we discuss the generalization performance on this inde-
pendent data set and compare with models based on pre-
viously published gene sets.
Methods
Tumour characteristics
Tissue collection and analysis were approved by the local
ethical committee. After obtaining informed consent,
tumour biopsies were sampled and immediately frozen in
liquid nitrogen during primary surgery and were taken
from three groups of patients: 4 from patients with stage I
disease, 30 from patients with platin-sensitive advanced
stage disease and 15 from patients with platin-resistant
advanced stage disease [3]. In this study, similarly as in the
pilot study, we will refer to these three groups as: I, As and
Ar respectively. The patient and tumour characteristics are
shown in table 1.
Microarray procedures
Microarray procedures were similar to our pilot study [2].
Briefly, each tumour in the independent data set was
hybridized twice (dye-swap) against the same common
reference pool from the pilot study on an array containing
21.372 probes enriched for genes related to ovarian can-
cer. From each patient, mRNA was amplified and labelled
with Cy3 and Cy5, according to Puskas and collaborators
[4]. All protocols can be downloaded from ArrayExpress
[5]. Microarray data and information recommended by
the MIAMI (Minimum Information About a MIcroarray
experiment) guidelines can be found on the ArrayExpress
website [6] (Accession number E-MEXP-995 for the inde-
pendent data set and E-MEXP-979 for the pilot data).
Microarray data analysis
The gene expression data were analysed using MATLAB 7
(R2006b). Pre-processing was done similarly as in our
pilot study. Briefly, each microarray in the independent
data set was analysed separately in the following order:
the intensities were background-corrected, log-trans-
formed and finally normalised using the intensity
dependent Lowess fit procedure. The mean of the replicate
and normalised log ratios was used as a measure for
expression. After pre-processing, first PCA and secondly
LS-SVM were used to analyse the data. PCA was used for
visualisation of the data while LS-SVMs were used for
building classification models. A p-value is considered
statistically significant if smaller than 0.05. All statistical
tests were two-sided unless mentioned otherwise. Exact
bionomial confidence intervals were calculated using SAS
9.1.3 statistical software.
PCA
The procedure followed during PCA analysis can be found
in Figure 1. This figure schematically shows the different
steps involving the pilot and the independent data set.
First, we rank the genes according to their differential
expression between the three classes (Kruskal Wallis test)
the pilot data and the top 3000 genes were selected. Then
PCA analysis was performed on the reduced pilot data setBMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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and the three largest principal components were selected
(i.e., the directions associated with the largest eigenval-
ues). Finally, we used the gene expression values from the
independent data set corresponding to the 3000 genes
that were previously selected in the pilot data set and pro-
jected this reduced independent data set in the space
defined by the three largest principal components in the
pilot data. Finally, the 3000 corresponding gene expres-
sion values were selected in the independent data set and
the reduced independent data set was projected in this
space.
LS-SVMs
Next, we used the pilot data set to build an LS-SVM to pre-
dict disease stage and an LS-SVM to predict the response
to platin-based chemotherapy (MATLAB scripts were
downloaded from LS-SVMlab version 1.5 [7,8]). In the
pilot study, an RBF kernel did not improve results there-
fore in all subsequent analysis a linear kernel was used.
Figure 2 shows the different steps in this analysis which
consists of the same steps for both two-class classification
problems. First, the genes were ranked according to the
differential expression between two classes using only the
pilot study data and the top 3000 genes in this ranking
were selected (Wilcoxon rank sum test). Next, the corre-
sponding gene expression values were selected in the
independent data set. Subsequently, an LS-SVM with lin-
ear kernel was trained using the reduced pilot data and
applied to predict the class of the samples in the inde-
pendent data set. This results in a estimate of the general-
ization performance of a model built only on the pilot
study data for both classification problems.
Comparison with other profiles
To assess the performance of models based on our data we
compared them with the performance of models based on
published gene sets that predict a broad range of out-
comes in ovarian cancer. It is difficult to directly apply the
published models on our data since multiple different
microarray platforms (e.g. one channel Affymetrix micro-
arrays(Uv95Av2, HumanGeneFl, U133A) or two-channel
custom arrays (cDNA)) have been used to derive these
Table 1: Tumour characteristics. Clinical information of the tumour samples in the independent data set
Class Ar (n = 15) Class As (n = 30) Class I (n = 4)
Mean Age (range), years 61.8 61.3 49
Histologic type
Serous 14 29 1
Endometrioid 1 - 2
Mucinous - - 1
Mixed carcinoma - 1 -
FIGO stage
I- - 4
III 9 28 -
IV 6 2 -
Differentiation grade
Grade 1 - 1 1
Grade 2 5 7 2
Grade 3 10 22 1
Operation
Primary surgery 6 22 4
Interval surgery after three courses of chemotherapy 3 8 -
Diagnostic biopsy, no surgery 6 - -
Residual tumour load after surgery
0 cm 8 24 4
0–1 cm - 1 -
1–2 cm - 4 -
> 2 cm 7 1 -
Time to progression after first-line chemotherapy
< 6 months 15 - -
6–12 months - - 1
> 12 months - 22 2
No recurrence - 8 1
Current status
No evidence of disease - 8 1
Alive with evidence of disease 1 8 1
Died of disease 14 14 2
Median follow-up, months 16 35 18BMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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gene sets. Therefore we adopted the strategy visualized in
Figure 3. First, the gene set is extracted from the literature
and, if not already done, the genes were translated to
HUGO (Human Genome Organization) gene symbols.
Then, we extracted, in both the pilot and independent
data set, the genes corresponding to the HUGO gene set
from the literature. Subsequently, our model building
strategy proceeds as previously described (see Figure 3).
We used gene sets related to the response on platin-based
chemotherapy [9-11], gene sets related to survival in epi-
thelial ovarian cancer (EOC) [12] or in advanced stage
serous EOC [13,14], gene sets discriminating between the
major histological types (serous, mucinous, clear cell and
endometrioid) [15,16], gene sets distinguishing between
normal ovarian tissue and disease [17,18], gene sets dis-
criminating between low malignant potential or border-
line disease and invasive disease [19], gene sets
differentiating between ovarian cancer tissue and meta-
static tissue [20] and a gene set predicting the presence of
disease at second look surgery [21]. These gene sets where
constructed based on affymetrix microarrays (HuGeneFl,
U95 set, U95Av2, U133A), different cDNA microarrays or
HPLC (High Performance Liquid Chromatography) fol-
lowed by ESI-TOF (Electrospray Ionization Time of
Flight) mass spectrometry.
Principal Component Analysis (PCA) Figure 1
Principal Component Analysis (PCA). Both the pilot and independent data set are shown. First, (A) gene selection is 
done using a Kruskal Wallis test. Then (B) PCA analysis is performed on this reduced pilot data set. Next (C), the correspond-
ing gene expression values are selected in the independent data set and finally (D) this reduced independent data set is pro-
jected on the three largest principal components calculated only on the pilot data set.BMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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Results
In this study we describe the results of the evaluation of
models developed based on the data from our previously
published pilot study [2] using PCA analysis or LS-SVMs
on independently gathered microarray data. Note that all
stage I patients in the pilot study had ovarian tumours
without recurrence while in the current study population
the four patients with stage I disease consist of 3 stage I
tumours with recurrence and 1 stage I tumour without
recurrence. Figure 4 shows the results of the PCA analysis.
This figure visualises the projection of the patients from
the independent data set belonging to the stage I, platin-
sensitive and platin-resistant group onto the three princi-
pal component directions calculated based on the pilot
study data. For all three groups, the data are scattered
around the origin which indicates that the principal com-
ponents computed based on the pilot data were not able
to reproduce the three classes in the independent data set.
Additionally, we did not observe a clear distinction
between the stage I patients with and without recurrence
(see Figure 4, top panel).
Secondly, we used LS-SVMs to assess if a supervised classi-
fication model can discriminate between the stage I and
advanced stage disease, and between platin-sensitive and
platin resistant disease. This resulted in a classification
accuracy of 97.96% (CI 19%–99%) for the distinction
between stage I and advanced stage disease which corre-
sponds to one stage I tumour out of four that was classi-
fied as an advanced stage tumour. Next, a classification
accuracy of 51.11% was obtained for the distinction
between platin-sensitive and platin-resistant disease. This
Model building procedure Figure 2
Model building procedure. LS-SVM model building procedure for disease stage, the model building procedure for response 
to platin-based chemotherapy is similar. First (A), the 3000 genes with the largest degree of differential expression between 
two classes in the pilot study are selected. Next (B), the corresponding gene expression values are selected in the independent 
data set. Subsequently, (C) an LS-SVM model is built using only the pilot data. Finally, (D) this model is used to predict the class 
of the samples in the independent data set which gives an estimate of the generalization performance.BMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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corresponds to five platin-resistant and eighteen platin-
sensitive tumours that were misclassified, corresponding
to a sensitivity of 67% (CI 38%–0.88%) and specificity of
40% (CI 23%–0.59%) when considering a platin resistant
patient as a positive
Table 2 shows the accuracy on the independent data set
for predicting stage and platin sensitivity of the models
based on the pilot data and previously published gene
sets. Most gene sets are able to predict ovarian cancer stage
reliably (ranging from 87.8%–97.96%). Five profiles were
less successful: Lancaster disease vs. normal (79.6%), Rob-
erts platin sensitivity vs. platin resistance (75.5%) and
both Lancaster ovarian cancer tissue vs. metastatic tissue
models (71.4% and 57.14%). When focusing on the pre-
diction of platin sensitivity, 5 of the published gene sets
predicted the majority class on the independent data set
resulting in 66.6% (30/45) classification accuracy. How-
ever, such a classifier has very little practical use since it
predicts the same class for all independent data set sam-
ples. Finally, the Lancaster metastasis model consisting of
25 genes performed best with an accuracy of 60% corre-
sponding to a sensitivity of 86% and specificity of 47%
when considering a platin resistant patient as a positive
(P-value 0.12, one sided binomial test).
Discussion
Recently, several studies have investigated the use of
microarrays to predict several clinically relevant outcomes
of ovarian cancer [9,10,12,13,15,21]. However, the iden-
tified gene sets or developed models in these studies have
not been properly evaluated on independently gathered
Model building procedure published gene sets Figure 3
Model building procedure published gene sets. Model building procedure for testing the performance of published gene 
sets that predict ovarian cancer outcomes. First (A), the gene set is extracted from the literature and the corresponding genes 
are selected in both the pilot and independent data set. Subsequently, (B) an LS-SVM model is built using only the pilot data and 
finally, (C) this model is used to predict the class of the samples in the independent data set which gives an estimate of the gen-
eralization performance of a gene set.BMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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data. Microarray technology is notorious for its low sig-
nal-to-noise ratio, suffering from many potential experi-
mental sources of error (e.g. dye effect, print-tip effect,
array effect) on top of the biological variation inherent to
the samples. Moreover due to the huge number of genes
(e.g. ~25.000) compared to the low number of samples
(~50), overfitting models is a real danger. This occurs
when models fit the training data too well and are not
capable of predicting new samples. Overfitting can only
be detected when using proper cross-validation tech-
niques or independent test set analysis. Only a true inde-
pendent test set – not used for determining pre-processing
parameters, selection of differentially expressed genes,
model building or model selection – can be used to esti-
mate the true performance of models [22]. For example,
we noticed a case of inappropriate use of a test set where
this data set was used to select the best model [10,22].
This implies that the model will perform well on this par-
ticular test set but, due to the high-dimensional nature of
microarray data, this performance might be impossible to
reproduce on truly independent data. Moreover, a
recently published review of published microarray studies
that focus on cancer related outcomes showed that the
most common flaw in classification studies is a biased
estimation of the accuracy (present in 12 of 28 studies
published in 2004 [23]). This illustrates that inappropri-
ate evaluation of classifiers based on microarray data is a
Results of the Principal Component Analysis (PCA) Figure 4
Results of the Principal Component Analysis (PCA). Visualization of the three principal component directions corre-
sponding to the largest variation in the pilot data after selection of the 3000 genes with the largest degree of differential 
expression (Kruskal-Wallis) and projection of the independent data set onto these principal components. * = individual pilot 
sample, + = individual independent data set sample, o = mean expression in each class in the pilot data, Δ = mean expression of 
the projected independent data set class; blue = stage I without recurrence; green = stage I with recurrence; red = platin-sen-
sitive advanced stage; black = platin-resistant advanced stage. Top panel) projection of the stage I independent data set sam-
ples, Middle panel) projection of the platin-sensitive advanced stage independent data set samples, Bottom panel) projection 
of the platin-resistant advanced stage independent data set samples.BMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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common problem when building models to predict can-
cer outcomes.
Although more data should be gathered on stage I
patients, the results presented in this paper indicate that
predicting the response to platin-based chemotherapy is
not straightforward and more subtle than predicting
advanced stage disease. Furthermore, since most pub-
lished studies lack a proper independent evaluation, their
results should be cautiously interpreted. We advocated the
use of microarrays based on the results from our pilot
study, but warned for overestimating the generalization
performance, as these results were based on a cross valida-
tion technique instead of using an independent data set.
Additionally, since the pilot study performance for pre-
dicting the response to platin-based chemotherapy was
not statistically significant, we searched for confirmation
on an independent test set. Therefore, we carried out a
new study to estimate the performance of models based
on independently gathered microarray data in an unbi-
ased way. The present results, both the PCA analysis and
the performance of the LS-SVM models, show that the
independent evaluation is disappointing. Only the LS-
SVM stage model performed well and was able to distin-
guish early stage and advanced stage disease on the inde-
pendent data set. The PCA analysis however demonstrated
that, for the three classes, the independent data did not
cluster to their corresponding class in the pilot study.
Additionally, the LS-SVM platin model was not able to
perform better than a random predictor. Therefore, we
argue that a gene expression study should be validated on
independently gathered data before the results can be con-
sidered for clinical use. Independently gathered data can
be influenced by subtle changes in sample preparation,
sample analysis and sample hybridizations, which can
deteriorate model performance. Even the techniques used
by the same lab might undergo subtle changes throughout
time, causing a drop in model performance when the
model is applied on new patient samples. It is unclear
whether published models are robust against these influ-
ences.
Additionally, ovarian cancer represents an immense vari-
ation in histological structure and biological behaviour
which complicates microarray based modelling. A large
number of samples is required to correctly represent the
complete microscopic spectrum. It is not unlikely that an
independent data set contains a different mix of tumour
samples with slightly different histological characteristics
compared to the pilot study, complicating independent
evaluation. Moreover, the quality of the samples has a
major effect on the ability to detect true differential
expression and subsequent model building. However in
most cases, including ours, only a limited number of sam-
ples with sufficient follow-up is available which limits our
ability to obtain a similar distribution of histopathology
in the pilot and independent data set, and also forces us
to use archival samples instead of new ones.
Table 2: Comparison with published gene sets. Accuracy of all published gene set models on the independent data set both when 
predicting stage and platin resistance ranked by stage accuracy. Gene sets have been named after the first author of the publication 
followed by a description of its relationship to patient outcome. References have been used when the same first author had multiple 
publications
Gene set first author Description Stage accuracy (%) Platin accuracy (%)
Ouellet low malignant potential/borderline disease vs. invasive disease: tumour tissue 97.96 55.56
Hibbs Disease vs. normal or other tissues 95.92 66.67*
Spentzos Residual disease vs. complete response at second look surgery 93.88 37.78
Lu Disease vs. normal 93.88 48.89
Helleman Platin sensitivity vs. platin resistance: differential expression 93.88 44.44
Ouellet low malignant potential/borderline disease vs. invasive disease: primary cultures 91.84 53.33
Zhu Clear cell vs. serous histology 91.84 66.67*
Lancaster [14] Short-term vs. long-term survival 91.84 44.44
Helleman Platin sensitivity vs. platin resistance: 16-gene predictive model 91.84 46.67
Berchuck Short-term vs. long-term survival 91.84 55.56
Schwartz Clear cell vs. other histological types 91.84 46.67
Hartmann Early vs. late relapse after platin based chemotherapy 91.84 66.67*
Spentzos Short-term vs. long-term survival 87.76 66.67*
Lancaster [14] Disease vs. normal 79.59 66.67*
Roberts Platin sensitivity vs. platin resistance 75.51 42.22
Lancaster [20] Ovarian cancer tissue vs. metastatic tissue: 27-gene predictive model 71.43 60.00#
Lancaster [20] Ovarian cancer tissue vs. metastatic tissue: differential expression 57.14 66.67*
*models predicting only the majority class (platin sensitive patients) on the independent data set
#best platin modelBMC Cancer 2008, 8:18 http://www.biomedcentral.com/1471-2407/8/18
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The comparison of the LS-SVM stage and LS-SVM platin
model with published genes sets confirmed that predict-
ing disease stage is easier than predicting response to pla-
tin-based chemotherapy. For predicting disease stage
many previously developed gene sets are able to distin-
guish both classes indicating that many genes change
when a tumour progresses from early to advance stage dis-
ease. Predicting the response to platin based chemother-
apy is more challenging. None of the previously
developed gene set models related to the response to pla-
tin based chemotherapy are able to predict this outcome
significantly better than chance. This indicates that these
gene sets do not generalize to our independently gathered
data set. Only the 27-gene model by Lancaster and col-
leagues [20], which distinguishes between primary ovar-
ian cancer and metastatic tissue, is able to predict the
response to platin based chemotherapy to some degree.
This gene set contains 12 genes which have previously
been shown to be involved in oncogenesis and 10 genes
which have been implicated in the p53 pathways. The per-
formance of this gene set on our independent data set pro-
vides some evidence that genes distinguishing between
primary and metastatic tissue also play a role in resistance
to therapy.
Conclusion
Our results show that an independent evaluation of mod-
els based on gene expression data is necessary to validate
models before considering subsequent steps to make
microarray analysis clinically available. Previously pub-
lished studies should be critically reviewed, in light of the
current results, to assess if the reported model perform-
ance is not overestimated by inappropriate use of a test set
and, if this is not the case, to consider if an independent
study would confirm the reported model performance.
Finally, prospective validation in multi-centre trials is nec-
essary before microarray technology can move to clinical
practice.
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